To assess the safety of FluMist vaccination
* To assess the safety of FluMist vaccination Rates of medically attended events in FluMist recipients, including serious adverse events (SAEs), anaphylaxis , urticaria, asthma, wheezing, pre-specified grouped diagnoses, and rare events potentially related to wild-type influenza, will be compared to rates in multiple non-randomized control groups. * To assess the safety of annual FluMist re-vaccination \[Rates of MAEs in the subset of children who receive FluMist in ≥2 consecutive years will be compared to rates in first-time vaccinees during the same season.\] * To assess the safety of FluMist vaccination in children previously vaccinated with trivalent inactivated influenza vaccine (TIV) \[Rates of MAEs in the subset of children who received one or more prior TIV vaccinations will be compared to rates in children who did not receive prior TIV.\]
Study Type
OBSERVATIONAL
Enrollment
29,296
One or two vaccinations with FluMist depending on prior vaccination status.
One or two injections of TIV depending on previous status.
no vaccine
Research Site
Oakland, California, United States
Assess Medically Attended Events(MAEs)of anaphylaxis,urticaria, asthma,wheezing,pre-specified grouped diagnoses,and rare events related to wild-type influenza,MAEs-qualify as SAEs,in:emergency department,clinic,and hospital setting.
Time frame: 1, 3, 21, or 42 days post dose; 6 months post dose; entire study period)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.